Novo shifts strategic focus toward diabetes and obesity treatment as the GLP-1 market heats up. The project is doubling down on these high-demand therapeutic areas, positioning itself to capitalize on the rapid expansion of glucose-like peptide-1 drug development and adoption. This move reflects broader industry recognition of GLP-1's blockbuster potential in the healthcare and biotech sectors. By narrowing its focus to these two key areas, Novo aims to deepen its expertise and accelerate product pipeline development. The GLP-1 market continues gaining momentum, with major players ramping up investments and clinical trials. Novo's strategic pivot signals confidence in the long-term growth trajectory of this space, suggesting the project sees significant runway for innovation and market capture in obesity and diabetes therapeutics.